Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

IMM60 & pembrolizumab in Melanoma and NSCLC

 IMP-MEL Trial Logo.jpg

Full Title

A phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC

Chief Investigator: Prof. Mark Middleton

Sponsor: University of Oxford

 

Status

Protocol approved, trial in set up.